Tirzepatide vs Semaglutide: What the Clinical Trials Showed
Licensed Medical Team
Laboratory Testing · As Indicated
Boca Raton · 20+ Yrs
Table of Contents
What Are GLP-1 Medications & How Do They Work?
GLP-1 weight loss medications work by mimicking glucagon-like peptide-1, a hormone your gut naturally releases after eating. At therapeutic doses, these medications suppress appetite at the brain level, slow gastric emptying, improve insulin sensitivity, and reduce food cravings — producing weight loss that far exceeds what diet and exercise alone can achieve in most patients.
The two leading medications are semaglutide (Ozempic for diabetes, Wegovy for weight loss) and tirzepatide (Mounjaro for diabetes, Zepbound for weight loss). Tirzepatide is the newer, more effective option — it activates both GIP and GLP-1 receptors, producing a dual hormonal effect that consistently outperforms semaglutide in clinical trials.
Key Takeaways
- GLP-1 medications reduce hunger neurologically — patients report genuinely not feeling hungry, not willpower-driven restriction
- Tirzepatide activates two hormone receptors (GIP + GLP-1); semaglutide activates one — producing superior weight loss
- Physician supervision, proper titration, and metabolic monitoring are essential for safety and best outcomes
- These are FDA-approved prescription medications with extensive Phase 3 clinical trial data — not supplements
Tirzepatide vs. Semaglutide: 2025 Clinical Data Compared
The SURMOUNT-1 trial (Jastreboff et al., NEJM 2022) demonstrated tirzepatide 15mg achieving 20.9% mean body weight reduction over 72 weeks — a result previously seen only with bariatric surgery. For a 250 lb patient, that’s approximately 52 lbs. The STEP-1 trial for semaglutide 2.4mg showed 14.9% reduction — still clinically significant, but meaningfully lower. Head-to-head data from SURMOUNT-5 confirmed tirzepatide produced 47% more weight loss than semaglutide at equivalent duration.
| Factor | Tirzepatide (Zepbound) | Semaglutide (Wegovy) |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 agonist | GLP-1 agonist only |
| Avg. Weight Loss | 20.9% (SURMOUNT-1) | 14.9% (STEP-1) |
| FDA Approval for Weight Loss | Zepbound — Nov 2023 | Wegovy — June 2021 |
| Dosing | Weekly injection; 2.5mg–15mg | Weekly injection; 0.25mg–2.4mg |
| Cardiovascular Benefit | Yes (SURPASS-CVOT data) | Yes (SELECT trial) |
| Brand Cost (monthly) | ~$900–$1,100 | ~$900–$1,350 |
| FDA-approved for chronic weight management | Yes — Zepbound | Yes — Wegovy |
What Results Can You Realistically Expect?
Results depend on starting weight, metabolic health, adherence, protein intake, and exercise. Based on clinical trial data and real-world patient outcomes, here is a typical tirzepatide timeline:
What the Tirzepatide Trial Data Showed Over Time
- Weeks 1–4 (2.5mg): Mild appetite reduction, GI adjustment. Average 2–4 lbs lost.
- Weeks 5–8 (5mg): Noticeable appetite suppression, cravings reduced. 1–2 lbs/week typical.
- Months 3–6: Peak weight loss velocity. Most patients lose 12–18 lbs in this window.
- Months 6–12: Dose optimization, plateau management. Total loss typically 15–22%.
- Year 2+: Maintenance dosing. Continued metabolic, cardiovascular, and body composition benefit.
Important: stopping the medication without a structured transition plan typically results in weight regain within 12 months. Our program includes a maintenance protocol to preserve long-term results.
Who Qualifies for GLP-1 Weight Loss in Boca Raton?
FDA approval guidelines require a BMI of 30+ (obese) or BMI 27+ with at least one weight-related health condition — hypertension, Type 2 diabetes, high cholesterol, or sleep apnea. our physician evaluates each patient individually and may extend benefit to patients with BMI 25–27 with significant metabolic syndrome on a case-by-case basis.
Your initial consultation includes a comprehensive medical history review, current medications, lab panel, and discussion of your goals. This is a full clinical evaluation — not a quick prescription visit.
Ready to Start Your GLP-1 Program in Boca Raton?
Schedule a physician consultation with our team at Brazelia Med Spa. Review your labs, health history, and goals — then receive a personalized protocol designed for you. See our GLP-1 weight loss program in Boca Raton for how the program is structured and what it includes.
How Brazelia Med Spa’s GLP-1 Program Works
Every patient is managed by our team at Brazelia Med Spa — with experience in hormone optimization, metabolic medicine, and integrative wellness. Every protocol is individualized.
- Initial Consultation + Labs: Comprehensive metabolic panel, HbA1c, thyroid, lipid panel, kidney/liver function, full hormone assessment.
- Personalized Dosing: Slow titration protocol minimizes side effects and improves adherence.
- Monthly Check-ins: Body composition, labs, appetite feedback, medication adjustments.
- Nutritional Guidance: Protein optimization (0.8–1g/lb lean mass), micronutrient support, meal timing for muscle preservation.
- Maintenance Planning: Structured weaning, habit consolidation, and continued metabolic support.
We prescribe the FDA-approved medications Zepbound and Wegovy where they are clinically appropriate for you following evaluation. Federal restrictions on compounding semaglutide and tirzepatide changed in 2025, and we do not offer compounded versions of these medications as a routine or lower-cost substitute for an available FDA-approved product.
Side Effects, Risks & How We Manage Them
The most common side effects are gastrointestinal — nausea, reduced appetite, loose stools. These are dose-dependent and typically resolve within 2–4 weeks of each dose increase. Our slow titration protocol is designed to minimize these.
| Side Effect | Frequency | Management |
|---|---|---|
| Nausea | 30–44% (mild-moderate) | Slow titration, small meals, anti-nausea if needed |
| Constipation | ~25% | Fiber, hydration, magnesium supplementation |
| Injection site reaction | ~5% | Site rotation, proper technique training |
| Muscle loss | Possible without intervention | Resistance training, protein targets, hormone support |
| Pancreatitis (rare) | <0.1% | Contraindicated with personal/family hx of MEN2 |
Absolute contraindications: personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia type 2 (MEN2). Every patient is screened for these and other contraindications by a prescribing provider before any medication is started.
Costs & Compounded Options
Brand-name GLP-1 medications cost approximately $700–$1,350 per month before any insurance benefit or manufacturer savings program. Your actual cost depends on the medication prescribed, your dose, your pharmacy and your coverage, and is confirmed with you before treatment begins. Financing is available through CareCredit, an independent third-party lender on its own terms.
A note on compounded medications. Compounded drugs are not FDA-approved. FDA does not review them before marketing for safety, effectiveness or manufacturing quality, and a pharmacy being registered as a 503B outsourcing facility does not mean any drug it prepares is FDA-approved. Since 2025 semaglutide and tirzepatide are no longer in shortage and the compounding pathways available during the shortage have closed. Where a compounded preparation is used at all, it is only because a prescriber has determined and documented that an FDA-approved product is not clinically appropriate for that individual patient.
Frequently Asked Questions
Is tirzepatide better than semaglutide for weight loss?
Yes, based on consistent clinical evidence. SURMOUNT-1 showed 20.9% body weight reduction for tirzepatide 15mg vs. 14.9% for semaglutide 2.4mg in STEP-1. Head-to-head data (SURMOUNT-5) confirmed tirzepatide produced 47% more weight loss than semaglutide. Both medications are effective; individual responses vary.
How long do I need to stay on GLP-1 medications?
GLP-1 medications are generally not short-term. Clinical data shows patients who stop regain most weight within 12 months without lifestyle consolidation. Many patients continue at a maintenance dose indefinitely. Our physicians creates individualized exit strategies when stopping is appropriate.
Does Brazelia Med Spa offer compounded semaglutide or tirzepatide?
Yes. We offer compounded tirzepatide and semaglutide from licensed 503B compounding pharmacies during FDA shortage periods and for patients who cannot afford brand-name pricing. Compounded medications are not FDA-approved finished products; we explain all differences at consultation.
Will I lose muscle mass on GLP-1 medications?
Without intervention, 25–40% of total weight lost may come from lean mass. Our program specifically addresses this: personalized protein targets (0.8–1g/lb lean mass), resistance training guidance, hormone panel review, and peptide therapy options for muscle preservation.
Can I get GLP-1 medications quickly in Boca Raton?
Yes. We offer same-week and next-week consultations. Every patient receives a consultation, in person or by telemedicine, before any prescription. We have established pharmacy relationships to minimize delays.
What does a GLP-1 consultation at Brazelia Med Spa cost?
Contact us for current pricing — we offer program tiers depending on monitoring frequency and included services. Financing available through CareCredit. Call 561.353.2265 or book online.
Licensed Medical Team Laboratory Testing · As Indicated Boca Raton · 20+ YrsStart Your Medical Weight Loss Journey Today
Brazelia Med Spa is a Boca Raton medspa offering integrated GLP-1 weight loss with hormone optimization, body composition analysis, and full metabolic monitoring.
Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. GLP-1 medications require physician evaluation and prescription. Individual results vary. Content reviewed by the Brazelia Med Spa team. Consult a qualified healthcare provider before starting any treatment.References & Citations
- Jastreboff AM, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” NEJM. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
- Wilding JPH, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” NEJM. 2021;384:989-1002. doi:10.1056/NEJMoa2032183
- Lincoff AM, et al. “Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.” NEJM. 2023;389:2221-2232. doi:10.1056/NEJMoa2307563
- FDA. “FDA Approves New Medication for Chronic Weight Management.” November 2023. fda.gov
- Obesity Medicine Association. “Obesity Algorithm 2025.” obesitymedicine.org